Table S3. Grade ≥3 Adverse Events Reported in >1 Patient[a] [n (%)]

	Rivoceranib N=80
Grade ≥3 adverse events reported in any patient	64 (80.0)
Hypertension	34 (42.5)
Neutropenia[b]	9 (11.3)
Stomatitis	6 (7.5)
Anemia	5 (6.3)
Fatigue	5 (6.3)
Pneumothorax	4 (5.0)
Back pain	4 (5.0)
Platelet count decreased	3 (3.8)
Weight decreased	4 (5.0)
Hypokalemia	3 (3.8)
Epistaxis	3 (3.8)
Hypoxia	3 (3.8)
Decreased appetite	3 (3.8)
Dyspnea	2 (2.5)
Diarrhea	2 (2.5)
Dysphagia	2 (2.5)
Nausea	2 (2.5)
Alanine aminotransferase increased	2 (2.5)
Aspartate aminotransferase increased	2 (2.5)
Blood alkaline phosphatase increased	2 (2.5)
Pneumonia	2 (2.5)
Seizure	2 (2.5)
Palmar-plantar erythrodysesthesia syndrome	2 (2.5)
Proteinuria	2 (2.5)

[a]Fatal adverse events occurred in 4 patients: epistaxis in 2 patients with nasal cavity tumors (nasopharynx and paranasal sinuses), one deemed related to rivoceranib per investigator; and acute respiratory failure associated with progressive disease in 2 patients; [b]Term includes neutropenia and neutrophil count decreased.